It's essentially a poison bill where they won't allow anyone to take controlling interest of the company by picking up several million shares on the cheap today and in the coming days. With 20 million in the bank and a Nasdaq listing, and the remaining IP and whichever direction they decide to go, it would be easy to be taken over. Like was pointed out, its 1.50 per share in cash. They wanted to minimize the chances of that happening while keeping bryostatin possibilities alive.
No doubt about it, its a long road ahead. No guarantees on the future of the drug. They'll be post hoc data mining anything thing they can for answers I suppose, so until then (likely months down the road) we won't know why or what went wrong, but it certainly did go wrong.
Biggest take I have is that AD is understood so poorly that understanding your own science isn't necessarily enough. I will always be on the lookout for novel approaches the disease, knowing nothing is a sure bet. No doubt there are things that can trigger defense mechanisms in your body. We just don't know how much help that will give when it comes to trials. Even with approved drugs out there, there is simply little relief. As has been posted today, the disease is devastating to families and its just so sad to take some of the hope off the table. My concern with trial #1 was patients were too far gone to be helped. Whether or not we get an opportunity to use it earlier in the progression remains to be seen and would be a long ways off IMO.
News 
Market Data 
Discover 
AI
